Luka Randic sadly and unexpectedly died during the preparation of this case report. He was a popular and caring doctor with a bright future ahead of him. He will be greatly missed by friends and colleagues alike.
A 63-year-old man attended the emergency department with a five-day history of vomiting and feeling generally unwell. He had a history of type 2 diabetes, hypertension and chronic renal impairment with a baseline creatinine of 169 µmol/L. His usual medication included metformin 850 mg tds which he had been taking for approximately nine years.
At triage, the patient was alert and oriented, had a respiratory rate of 28/minute with SpO 2 of 97% on air, was cardiovascularly stable with a heart rate of 80/minute, blood pressure 160/50 mm Hg and had a measured blood glucose of 4.9 mmol/dL. While awaiting further assessment, the patient suddenly became agitated then collapsed. His heart rate dropped to 35/min and blood pressure to 80 mm Hg systolic. The patient received 300 µg atropine IV and his heart rate increased to 90/min with no change in blood pressure or mental status. The patient then became apnoeic and suffered a pulseless electrical activity cardiac arrest.
The patient received six minutes of cardiopulmonary resuscitation (CPR) with mask ventilation followed by orotracheal intubation and mechanical ventilation. He received 3 mg atropine and 2 mg of adrenaline IV. Spontaneous cardiac output returned but he did not regain consciousness or respiratory effort. Central venous access was secured and a noradrenaline infusion was started. His arterial blood gas postcardiac arrest revealed a severe metabolic acidosis with a raised anion gap as shown in Table 1 .
Renal function suggested acute on chronic renal impairment (Na + 141 mmol/L, K + 7.1 mmol/L, urea 28.8 mmol/L, creatinine 1,366 µmol/L). A 12-lead ECG showed sinus tachycardia with no ischaemic changes. On echocardiography a hyperdynamic left ventricle with no wall motion abnormality or significant valve abnormality was seen. The chest X-ray revealed cardiomegaly only. CT scan of the head and abdomen were normal.
The patient was transferred to the intensive care unit (ICU). A provisional diagnosis of septic shock and metforminassociated lactic acidosis (MALA) was made. Metformin was stopped. The patient had a septic screen performed on specimens of urine, sputum and blood that subsequently revealed no growth. Intravenous clarithromycin and gentamicin were started for sepsis of unknown origin, along with 200 mg hydrocortisone per 24 hours for reversal of shock.
His acidosis progressively improved and by 36 hours after admission he was ventilated with FiO 2 0.6 with pH 7.254, pCO 2 6.75 kPa, pO 2 29.16 kPa, bicarbonate 24.5 mmol/L, BE -2.9 mEq/L and lactate 1.4 mmol/L. He rapidly weaned from vasopressors and mechanical ventilation and by day three he was extubated.
The patient was anuric on admission to ICU and underwent continuous haemofiltration with lactate-free bicarbonate-based replacement fluid for five days. He had sessions of haemodialysis on days seven and eight, but was free of renal
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We report the case of a 63-year-old man who suffered a witnessed pulseless electrical activity cardiac arrest on presentation to the emergency department. Despite a profound post-arrest acidosis (pH 6.48) he went on to make an unexpectedly good recovery. He was treated for metformin-associated lactic acidosis (MALA) and septic shock, although the origin of the sepsis was never confirmed. We discuss the growing evidence against the existence of MALA as a lone diagnosis and the aetiology of post-cardiac arrest metabolic acidosis. replacement thereafter. He was discharged from critical care on day seven. His recovery on the ward was delayed due to development of Clostridium difficile toxin-positive diarrhoea. He was discharged home on day 19. On discharge his urea was 8.8 mmol/L and creatinine 238 µmol/L. At follow-up 14 weeks later he reported he had again reached his baseline physical function. He described symptoms of increased anxiety and depression which he attributed to his time in the ICU.
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Lactic acidosis is defined as an acidaemia (arterial pH <7.35) with increased blood lactate concentration (lactate >5 mmol/L). Patients presenting with shock with blood lactate concentrations of >10 mmol/L have up to 83% mortality. 1 The Cohen and Woods classification 2 divides lactic acidosis into two subgroups -type A, where tissue hypoxia is present, and type B, without tissue hypoxia. Type B lactic acidosis may be associated with increased lactate generation (impairment of cellular oxygen utilisation by toxins, hereditary disease or seen in some malignancies), or reduced lactate clearance (liver disease). Patients will often have a combination of type A and B lactic acidosis. Metabolic acidosis with a raised anion gap is caused either by ingestion or increased generation of acids. These include lactic acidosis (lactate), ketoacidosis (hydroxybutyrate, acetoacetate, lactate), uraemic acidosis (phosphate, sulphate) and salicylate poisoning (salicylate, lactate). 3 Metformin is a biguanide oral hypoglycaemic that has been shown to produce beneficial effects in glycaemic control, prevention of diabetic complications and reduced mortality in type 2 diabetes mellitus. 4 Metformin improves hepatic and peripheral sensitivity to insulin, reduces gluconeogenesis and increases insulin-stimulated uptake and utilisation of glucose in the periphery. Even in overdose, patients usually remain euglycaemic. 5 Biguanides have been in medical use for over 50 years. The first episode of biguanide-associated acidosis was reported in 1959 with phenformin, which was withdrawn from use in the UK in 1982. 6 This led to the suspicion that lactic acidosis may be a complication common to all biguanides. Metformin use is contraindicated in patients with a predisposition to cellular hypoxia such as those with chronic renal impairment, liver dysfunction and/or congestive heart failure, as well as in patients over the age of 65 years. In practice, this is commonly disregarded, with between 54% and 73% of patients on metformin reported to have at least one contraindication. 7, 8 Conditions potentially leading to tissue hypoxia such as strenuous exercise, excess alcohol and dehydration have been suggested to trigger decompensation. It has been suggested that under these conditions metformin-related inhibition of gluconeogenesis allows excessive accumulation of precursors such as alanine, pyruvate and lactate.
Numerous case reports of MALA are in the literature. Mortality in reported cases of metformin-associated lactic acidosis is 42-50%. 5 Many cases describe metformin overdose 9 or acidosis in combination with sepsis and dehydration 10 and hypothermia. 3 Treatment is typically supportive with intubation, ventilation, inotropic support, buffer infusions and haemofiltration or haemodialysis. 11 Many of these case reports describe profound acidosis (pH <7.0), relatively rapid reversal of acidosis and relatively good neurological outcome.
Despite the many case reports of metabolic acidosis in patients taking metformin, there is now debate as to whether metformin actually predisposes to lactic acidosis. Unlike the withdrawn drug phenformin, metformin does not impair oxidative phosphorylation in the liver, but impairs hepatic gluconeogenesis without altering lactate turnover or lactate oxidation. A recent Cochrane review of prospective comparative trials and observational cohort studies concluded that treatment with metformin is not associated with increased risk of lactic acidosis. 5 The incidence of lactic acidosis was 5.1 cases per 100,000 patient years in patients treated with metformin, and 5.8 cases per 100,000 patient years in diabetics not treated with metformin. This study did not specifically assess the frequency of acidosis in patients with a contraindication to metformin. However, 97% of included studies allowed recruitment of patients with at least one contraindication to metformin use and 24% of participants were over the age of 65. There is no clear relationship between dose, duration of treatment and development of lactic acidosis. 3 Normal metformin levels in treated individuals are 1-2 mg/L; however in severe acidosis, metformin levels are seldom found to correlate to severity of acidosis or to mortality. In a retrospective study examining emergency admissions in type 2 diabetics, admission with metabolic acidosis was found more often in patients treated with insulin or sulphonylureas than in those treated with metformin. 12 All cases were associated with concomitant illness that could have caused severe lactic acidosis. As the existence of metformin-induced acidosis becomes less likely, its use in patients previously believed to be at risk (ie those with renal impairment) is becoming more widespread.
Our case is unusual in several respects. It is rare to make a complete neurological recovery from such a profound acidosis. The lowest recorded arterial pH for a patient surviving what was reported to be metformin-associated acidosis is 6.3, but further details of the case are unknown. 13 This report aside, if metformin-induced acidosis exists, we believe our case has the lowest temperature-corrected pH for a surviving patient with the condition. There is a case with a similar pH -6.49 (temperature uncorrected 6.38) reported, where associated hypothermia (29 O C) was believed to have contributed to a good outcome. Hypothermia decreases cerebral oxygen demand, intracranial pressure and reduces glutamate levels and oxygen-free radical production. 14 Our patient is also unusual because he suffered a cardiac arrest. We are aware of one other case report of an adult patient who had a more profound acidosis post-cardiac arrest who went on to make a full neurological recovery. The report describes a 24-year-old male who survived near-drowning in sea water. 15 His post-resuscitation pH was 6.33 and he had a full neurological recovery, which may again have been partly because of hypothermia at the time of arrest. We are unaware of any other patient with a lower post-cardiac arrest pH (6.48) who made a full neurological recovery.
Case reports
Metabolic acidosis following cardiac arrest is due to imbalance between tissue oxygen supply and demand that may be further compounded by respiratory acidosis. Hyperlactaemia reflects tissue ischaemia, and low adenosine triphosphate levels and contributes about 50% of the post-arrest metabolic acidosis. Recent work based on the Stewart-Figg analysis of acid-base suggests that a large strong-ion gap (33%) and hyperphosphataemia (13%) also make major contributions. Strong compensating responses include hypochloraemia, hyperkalaemia and hypoalbuminaemia. 16 Lactate increases progressively through the period of cardiac arrest and remains high during resuscitation. 17, 18 Lactate has been suggested as a predictor of down-time during cardiopulmonary arrest, 18 and to a limited extent as a determinant of prognosis. Lower lactate at the return of spontaneous circulation and effective clearance of lactate by metabolism at 12 hours post-arrest is associated with a more favourable outcome. 19 With increasing lactate, functional neurological recovery is more likely to be unfavourable. In a retrospective study of survivors of out-of-hospital VF cardiac arrest, only at very high levels (lactate >16.3 mmol/L) could unfavourable neurological recovery be detected with 100% specificity, but low sensitivity 16% (n=167 out-of-hospital arrests). Lactic acidosis is not a reliable indicator of the severity of cerebral hypoxia in the individual patient. 20 Most work on the physiology of cardiac arrest in humans is based on out-ofhospital cardiac arrest where a prolonged time without CPR and cerebral anoxia may occur and may not accurately model the situation of a witnessed arrest in the emergency department. CPR was initiated promptly in this case and it is likely that the lactic acidosis in our patient reflects prolonged relative hypoxia prior to cardiac arrest rather than hypoperfusion during resuscitation that would normally be associated with cerebral hypoxia.
In summary, our patient presented with severe lactic acidosis of unclear origin. His presentation is similar to multiple previous case reports attributed to MALA. Despite these case reports, more recent evidence suggests that lactic acidosis is no more common with metformin treatment than without, and may in fact be due to systemic metabolic dysfunction triggered by concurrent critical illness. Although no focus of infection was isolated, it is likely the cause of his profound metabolic acidosis was septic shock.
Survival with good neurological outcome is possible where effective resuscitation is initiated promptly and profound postarrest lactic acidosis is due to relative tissue hypoxia prior to arrest rather than tissue (and cerebral) hypoxia at the time of arrest.
